|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 19, 2019 ) "Market Overview
Global Non-Hodgkin Lymphoma Therapeutics market is expected witness a CAGR of 7.4% during the forecast period. Certain factors that are driving the market growth include rise in prevalence of NHL, demand for innovative drugs and novel technologies, and increase in number of FDA approval for NHL therapy drugs.
In addition, increase in public awareness about NHL, robust drug pipeline for the treatment of the disease, improved diagnostic techniques to detect NHL, and increase in the prevalence of non-Hodgkin lymphoma are factors fuelling the NHL therapeutics market across the globe.
However, high cost of NHL drugs and various complications associated with them are acting as a major restraint for the non-Hodgkin lymphoma therapeutics market. Additionally, increasing rituximab resistance and stringent regulatory guidelines are also limiting the growth of the market.
Scope of the Report
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or just lymphoma) is cancer which starts in white blood cells called lymphocytes, which are part of the body’s immune system. NHL usually starts in lymph nodes or other lymph tissue, but sometimes it can affect the skin.
Request a sample of Non-Hodgkin Lymphoma Therapeutics Market report @ http://www.arcognizance.com/enquiry-sample/454174
Key Market Trends
Radiation Therapy is Expected to Hold Significant Market Share in the Type of Therapy
Radiotherapy is the use of high-energy beams or particles to kill cancer cells, and may be delivered from a source outside the body, i.e. external beam radiation or internally such as brachytherapy. Usually, radiation treatments are given five days per week for several weeks. Radiation therapy is most effective when this kind of lymphoma is only found in one part of the body. For non-Hodgkin disease, radiation therapy is used in the early stages of the diseases. In case of advanced lymphomas, radiation therapy is used along with the chemotherapy for better results. If the lymphoma is wide spread, palliative radiotherapy is very helpful. Radiotherapy is often very good at destroying non-Hodgkin disease cells. It mainly helps in relieving from the symptoms caused by the lymphomas.
Asia Pacific is Expected to Show Highest Growth Rate in the Forecast Period
The non-Hodgkin lymphoma therapeutics market is segmented by type of treatment and geography. By geography the market is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America. North America dominates the non-Hodgkin lymphoma therapeutics market due to increasing technological advancements and the rising incidences of NHL in the country. Asia-Pacific is also expected to propel the non-Hodgkin lymphoma therapeutics market owing to factors, such as increasing accessibility to healthcare facilities in the region and increasing prevalence of NHL. According to the research article published in 2018, it was estimated that the incidence rate of non-Hodgkin lymphoma was 7.11 per 100 000 per year in China. As the incidence and prevalence of non-Hodgkin lymphoma are increasing year on year many manufacturing companies are investing to develop novel drug therapies to meet the growing demand of therapeutics. Moreover, according to the research article published in 2015, “Cancer Prevention Research in China”, it was observed that the Chinese government has sponsored several large- and small-scale screening programs for the early detection of different cancers. Hence, with the growing awareness of the disease, increasing government initiatives, and increase in the prevalence and incidence of disease, the market is expected to grow over the forecast period.
Access this report of Non-Hodgkin Lymphoma Therapeutics Market @ http://arcognizance.com/report/non-hodgkin-lymphoma-therapeutics-market-growth-trends-and-forecast-2019-2024
Competitive Landscape
The global Non-Hodgkin Lymphoma Therapeutics market is highly competitive and consists of a few major players. Companies like Accredo Health Group Inc., AstraZeneca, Baxter International Inc., Bayer AG, Celgene Corp., Cephalon Inc., Eli Lilly and Co., F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc, Spectrum Pharmaceuticals, among others, hold the substantial market share in the Non-Hodgkin Lymphoma Therapeutics market.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support
Buy The Report @ http://www.arcognizance.com/purchase/454174
Major Point of TOC:
Chapter One: INTRODUCTION
Chapter Two: RESEARCH METHODOLOGY
Chapter Three: EXECUTIVE SUMMARY
Chapter Four: MARKET DYNAMICS
Chapter Five: MARKET SEGMENTATION
Chapter Six: COMPETITIVE LANDSCAPE
Chapter Seven: MARKET OPPORTUNITIES AND FUTURE TRENDS
Request a sample of Non-Hodgkin Lymphoma Therapeutics Market report @ http://www.arcognizance.com/enquiry-sample/454174
About Us:
www.arcognizance.com is an initiation in this new era of “analysis @ thought.” We are on a mission to replace the conventional research programs and give way to the latest methods and information for the organizations. We have created this hub of analytical research papers where you can get an access to the latest and the best research papers coming out from some reliable and budding research houses. After the advent of “new analytics""based on the data collection facilities of big data, the face of ""business research facilities"" has changed drastically. With ARC our experts have created a bookshelf where you can check out the research reports that are an outcome of the progression of knowledge in various industry sectors. Alongside you can also check some research papers, market reports, and forecasts that are talking about the ""out of the box""developments in the market.
Contact US:
Name: Analytical research cognizance
Address: 100 Church Street,
8th floor, Manhattan,
New York 10007
Phone: +1 (646) 434-7969 +91 90967 44448
Email: enquiry@arcognizance.com
Follows to Twitter : https://twitter.com/ARCognizance
Follows to Linkdin : https://www.linkedin.com/company/arcognizance"
Analytical Research Cognizance
Avanti dengale
+91 90967 44448
avanti.dengale@arcognizance.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
